# A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

> **NCT02960906** · PHASE2 · COMPLETED · sponsor: **Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie** · enrollment: 200 (actual)

## Conditions studied

- Clear Cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Pazopanib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT02960906
- **Lead sponsor:** Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-31
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-15
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960906, "A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02960906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*